Clinical trials
catalyst calendar across sponsors →Studies where DTIL is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional · 1 observational · 1 with posted results
Held by 6 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, Squarepoint Ops LLC, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, +1 more) · FINRA short interest 10.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Long-term Observational Study in Participants Who Have Received PBGENE-HBVNCT07254208observationalSafety to assess frequency, severity, and outcome of delayed adverse events | — | Enrolling by invitation | Biological: PBGENE-HBV | Chronic HBV Infection | 45 | Jan 2040 | ≤ 4,913 d | 2026-04-22 |
| PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)NCT07429240Incidence, severity, and causality of treatment-emergent adverse events and serious adverse eventsOpen-label · Treatment | Phase 1/2 | Recruiting | Biological: PBGENE-DMD (IV) | Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD | 18 | Nov 2029 | ≤ 1,199 d | 2026-06-23 |
| Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis BNCT06680232Safety to Assess Treatment-emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 1 | Recruiting | Biological: PBGENE-HBV | HEPATITIS B CHRONIC | 45 | Dec 2026 | ≤ 134 d | 2026-08-14 |
| Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing MalignanciesNCT04649112Maximum Tolerated Dose (MTD)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Genetic: PBCAR19B | CD19 Expressing Malignancies, Hematologic Malignancy | 13 | 2022-12-22actual | — | 2024-07-26 |
| A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple MyelomaNCT04171843Maximum Tolerated Dose (MTD) of PBCAR269ANon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Study was terminated due to lack of sufficient therapeutic effect | Genetic: PBCAR269A · Drug: Fludarabine, Cyclophosphamide, Nirogacestat | Relapsed/Refractory Multiple Myeloma | 48 | 2022-10-19actual | — | 2023-09-21 |
| Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLLNCT04030195results2023-01-31Maximum Tolerated Dose (MTD)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Genetic: PBCAR20A · Drug: Fludarabine, Cyclophosphamide | Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory, Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-cell Chronic Lymphocytic Leukemia, B-cell Non Hodgkin Lymphoma, Small Lymphocytic Lymphoma | 18 | 2021-06-24actual | — | 2023-01-31 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19